VEGF-targeted therapies have shown activity in ovarian cancer, and one of them, bevacizumab, has been recently approved in this disease. Aflibercept is an antiangiogenic soluble fusion protein that inhibits VEGF-mediated signaling. In ovarian cancer, phase II trials with aflibercept have shown a significant benefit in the control of malignant ascites but with a lower response rate than expected.
We report the case of a patient with relapsed ovarian cancer treated with aflibercept in fourth line, who experienced a prolonged response during more than two years with good tolerance. The duration of response to aflibercept was longer than that of the three previous lines of therapy (including the initial carboplatin-paclitaxel regimen) and ascites did not reappear. Further clinical research with this drug in ovarian cancer to identify patients who benefit most is warranted.
Tumori 2015; 101(1): e29 - e31
Article Type: CASE REPORT
AuthorsAndrés Redondo, Beatriz Castelo, Alvaro Pinto, Pilar Zamora, Enrique Espinosa
- • Accepted on 22/01/2014
- • Available online on 24/01/2015
- • Published online on 20/03/2015
This article is available as full text PDF.
- Redondo, Andrés [PubMed] [Google Scholar] , * Corresponding Author (email@example.com)
- Castelo, Beatriz [PubMed] [Google Scholar]
- Pinto, Alvaro [PubMed] [Google Scholar]
- Zamora, Pilar [PubMed] [Google Scholar]
- Espinosa, Enrique [PubMed] [Google Scholar]
Medical Oncology Department, Hospital Universitario La Paz, Madrid - Spain